KDR and medullary thyroid gland carcinoma: Vandetanib targets RET, vascular endothelial growth factor receptor-2 and -3 (VEGFR2/3), and epidermal growth factor receptor (EGFR) signaling that contribute to the growth and invasiveness of MTC.